Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Spark Therapeutics, Inc. (ONCE)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/25/2019 |
GN
| Spark Therapeutics Wins Prix Galien USA Award for LUXTURNA® (voretigene neparvovec-rzyl) as Best Biotechnology Product |
| 09/18/2019 |
GN
| Paralympic Skier Danelle Umstead Teams Up with Spark Therapeutics to Help People Living with Inherited Retinal Diseases (IRDs) Access Genetic Testing |
| 08/27/2019 |
GN
| Spark Therapeutics Announces Change of Location for Annual Meeting of Stockholders |
| 04/17/2019 |
GN
| Spark Therapeutics Announces Sponsorship of Believe Limited's First-Ever Science Fair for the Hemophilia Community at 2019 National Hemophilia Foundation's Bleeding Disorders Conference |
| 04/15/2019 |
GN
| Spark Therapeutics (ONCE) Merger Class Action Lawsuit: Halper Sadeh LLP Announces Filing of Shareholder Class Action Lawsuit Against Spark Therapeutics, Inc. Concerning Its Proposed Merger With Roche Holdings, Inc. – ONCE |
| 04/04/2019 |
GN
| Rigrodsky & Long, P.A. Files Class Action Suit Against Spark Therapeutics, Inc. |
| 03/26/2019 |
GN
| MERGER ALERT – CMTA and ONCE: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies |
| 03/04/2019 |
GN
| MERGER ALERT – LABL and ONCE: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies |
| 02/26/2019 |
GN
| MERGER ALERT – LABL, CMTA and ONCE: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies |
| 02/25/2019 |
GN
| Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Spark Therapeutics, Inc. (ONCE) on Behalf of Stockholders and Encourages ONCE Investors to Contact the Firm |
| 02/25/2019 |
GN
| Spark Therapeutics Enters into Definitive Merger Agreement with Roche |
| 02/21/2019 |
GN
| New Research Coverage Highlights General Electric, Redfin, Splunk, Spark Therapeutics, Innospec, and Hemispherx BioPharma — Consolidated Revenues, Company Growth, and Expectations for 2019 |
| 02/19/2019 |
GN
| Spark Therapeutics Reports 2018 Financial Results and Recent Business Progress |
| 01/02/2019 |
GN
| Spark Therapeutics to Participate in J.P. Morgan Healthcare Conference |
| 12/02/2018 |
GN
| Spark Therapeutics Announces Updated Data on SPK-8011 from Ongoing Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 60th American Society of Hematology (ASH) Annual Meeting and Exposition |
| 11/28/2018 |
GN
| Analysis: Positioning to Benefit within Real Goods Solar, Natural Resource Partners LP, Spark Therapeutics, Social Reality, Rapid7, and BiondVax Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results |
| 11/23/2018 |
GN
| European Commission Approves Spark Therapeutics' LUXTURNA® (voretigene neparvovec), a One-time Gene Therapy for Inherited Retinal Disease Caused by Confirmed Biallelic RPE65 Mutations |
| 11/06/2018 |
GN
| Spark Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Progress |
| 10/29/2018 |
GN
| Spark Therapeutics Presents Three Post-hoc Analyses from Phase 3 Clinical Trial of LUXTURNA® (voretigene neparvovec-rzyl) at American Academy of Ophthalmology Annual Meeting |
| 10/25/2018 |
GN
| Spark Therapeutics Launches New Initiative to Raise Awareness of the Importance of Genetic Testing for People Living with Inherited Retinal Diseases |
| 10/08/2018 |
GN
| Spark Therapeutics Announces New Preclinical Data for Pompe Disease Gene Therapy Candidate |
| 09/25/2018 |
GN
| Spark Therapeutics gibt zustimmende Bewertung des Ausschusses für Humanarzneimittel für die einmalig verabreichte Gentherapie LUXTURNA® (Voretigen Neparvovec) in der Europäischen Union bekannt |
| 09/25/2018 |
GN
| Spark Therapeutics Annuncia il Parere positivo del CHMP per la Terapia Genica una tantum LUXTURNA® (voretigene neparvovec) nell??Unione europea |
| 09/21/2018 |
GN
| Spark Therapeutics Announces Positive CHMP Opinion for One-time Gene Therapy LUXTURNA® (voretigene neparvovec) in the European Union |
| 08/24/2018 |
GN
| Report: Exploring Fundamental Drivers Behind Fiesta Restaurant Group, Emerge Energy Services LP, Collegium Pharmaceutical, Cutera, Resources Connection, and Spark Therapeutics ??? New Horizons, Emerging Trends, and Upcoming Developments |
| 08/07/2018 |
GN
| Spark Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Progress |
| 08/03/2018 |
GN
| Spark Therapeutics wurde vom Philadelphia Business Journal zum zweiten Mal in Folge als einer von Philadelphias „besten Arbeitgeber“ ausgezeichnet |
| 08/03/2018 |
GN
| Spark Therapeutics Recognized for Second-straight Year as One of Philadelphia's “Best Places to Work” by the Philadelphia Business Journal |
| 07/31/2018 |
GN
| Spark Therapeutics veranstaltet am Dienstag, 7. August, um 8.30 Uhr ET (Ostküstenzeit) eine Telefonkonferenz, um über die Unternehmens- und Finanzergebnisse des zweiten Quartals und die neuesten Geschäftserfolge zu sprechen |
| 07/31/2018 |
GN
| Spark Therapeutics to Host Conference Call on Tuesday, Aug. 7 at 8:30 a.m. ET to Discuss Second Quarter Results and Recent Business Highlights |
| 05/22/2018 |
GN
| Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events |
| 05/08/2018 |
GN
| Spark Therapeutics Reports First Quarter 2018 Financial Results and Recent Business Progress |
| 05/01/2018 |
GN
| Spark Therapeutics to Host Conference Call on Tuesday, May 8 at 8:30 a.m. ET to Discuss First Quarter Results and Recent Business Highlights |
| 04/30/2018 |
GN
| Spark Therapeutics Sells Priority Review Voucher for $110 Million |
|
|
|